Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 25Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 17Lung Neoplasms 14Neoplasms 13Breast Neoplasms 9Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Melanoma 5Carcinoma, Transitional Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Neoplasm Metastasis 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2

Interventions

pembrolizumab 4atezolizumab 3Cetuximab 3olaparib 2Trastuzumab 2Docetaxel 2zimberelimab 1tocilizumab 1spartalizumab 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1encorafenib 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumors × atezolizumab × 90 days × Clear all
NCT04303858 2026-06-02

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
189 enrolled
Other solid neoplasm

Solid Tumors

NCT04250155 2026-05-26

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Active not recruiting
195 enrolled
Other solid neoplasm

Solid Tumors

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡